ALZAMEND NEURO INC
ALZN · NASDAQ
Updated at 2026-10-14 09:31:18
- Today's High
- $1.42
- Today’s Low
- $1.30
%22%2F%3E%0A%3Cpath%20id%3D%22%26%23230%3B%26%23150%3B%26%23135%3B%26%23230%3B%26%23161%3B%26%23163%3B%26%23230%3B%26%23154%3B%26%23151%3B%26%23232%3B%26%23167%3B%26%23146%3B%22%20d%3D%22M48.3363%2013.4132H60.2082L46.795%205.72205e-06V11.8719C46.795%2012.7231%2047.4851%2013.4132%2048.3363%2013.4132Z%22%20fill%3D%22var(--fill-0%2C%20%23474741)%22%2F%3E%0A%3Cpath%20id%3D%22%26%23230%3B%26%23148%3B%26%23190%3B%26%23229%3B%26%23164%3B%26%23167%3B%26%23233%3B%26%23149%3B%26%23156%3B%22%20fill-rule%3D%22evenodd%22%20clip-rule%3D%22evenodd%22%20d%3D%22M11.3812%2020.3725C16.7977%2014.9559%2025.5803%2014.9559%2030.9969%2020.3725C36.413%2025.789%2036.4131%2034.5707%2030.9969%2039.9872C26.0109%2044.973%2018.1729%2045.3699%2012.7335%2041.1769L2.54298%2051.3684L0%2048.8254L10.1915%2038.6329C5.99993%2033.1937%206.39609%2025.3579%2011.3812%2020.3725ZM28.4539%2022.9155C24.4418%2018.9033%2017.9363%2018.9033%2013.9241%2022.9155C9.91245%2026.9275%209.91241%2033.4322%2013.9241%2037.4442C17.9362%2041.4562%2024.4418%2041.4562%2028.4539%2037.4442C32.4656%2033.4322%2032.4656%2026.9275%2028.4539%2022.9155Z%22%20fill%3D%22var(--fill-0%2C%20%235D5D56)%22%2F%3E%0A%3C%2Fg%3E%0A%20%20%3C%2Fsvg%3E%0A%3C%2Fsvg%3E%0A)
Candlestick trends are for reference. Refer to the trading page for actual data.
Key Statistics
- Previous Open
- $1.40
- Previous Close
- $1.31
- Volume
- 17.03K
- Market Cap
- $6.32M
- P/E Ratio
- --
- EPS
- $-2.27
Previous Day Range
52-Week Range
Company Overview
- Sector
- HEALTHCARE
- Industry
- Biotechnology
- Sub-industry
- BIOTECHNOLOGY
- Headquarters
- 3480 PEACHTREE ROAD NE, ATLANTA, GA, UNITED STATES, 30326
- Country
- US
- Listing Date
- 2021-06-15
- Fiscal Year End
- April
- Shares Outstanding
- 4.79M
- CIK
- 0001677077
- Website
- alzamend.com
Alzamend Neuro Inc. is an innovative biotechnology company poised to revolutionize the treatment landscape for neurodegenerative diseases, especially Alzheimer's disease. Utilizing a proprietary drug development platform and a robust intellectual property portfolio, the company is strategically positioned to meet significant unmet medical needs in the pharmaceutical market. With a commitment to advancing its therapeutic candidates through rigorous clinical trials and fostering strategic partnerships, Alzamend Neuro aims to enhance patient quality of life and make substantial contributions to the neurotherapeutics sector. Its focused approach on critical neurological health challenges presents a compelling investment opportunity within the biotech industry.
Financial Metrics
Revenue
2026-07-31
$0
2026-04-30
$0
2026-01-31
$0
2025-10-31
$0
Operating Expenses
2026-07-31
$2.99M
2026-04-30
$2.84M
2026-01-31
$2.19M
2025-10-31
$998.1K
Net Income
2026-07-31
-$3.02M
2026-04-30
-$2.86M
2026-01-31
-$2.19M
2025-10-31
-$1M
Net Profit Margin
2026-07-31
--
2026-04-30
--
2026-01-31
--
2025-10-31
--
Earnings Per Share
2026-07-31
$-0.68
2026-04-30
$-0.74
2026-01-31
$-0.58
2025-10-31
$-0.30
Earnings Before Interest, Taxes, Depreciation, and Amortization
2026-07-31
-$2.99M
2026-04-30
-$2.84M
2026-01-31
-$2.16M
2025-10-31
-$970.42K
Effective Tax Rate
2026-07-31
--
2026-04-30
--
2026-01-31
--
2025-10-31
--
| Item | 2026-07-31 | 2026-04-30 | 2026-01-31 | 2025-10-31 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Operating Expenses | $2.99M | $2.84M | $2.19M | $998.1K |
| Net Income | -$3.02M | -$2.86M | -$2.19M | -$1M |
| Net Profit Margin | -- | -- | -- | -- |
| Earnings Per Share | $-0.68 | $-0.74 | $-0.58 | $-0.30 |
| Earnings Before Interest, Taxes, Depreciation, and Amortization | -$2.99M | -$2.84M | -$2.16M | -$970.42K |
| Effective Tax Rate | -- | -- | -- | -- |
FAQs
Risk Warning
Stock prices can be highly volatile and may rise or fall sharply in a short period. Digital asset and derivative products involve additional risks such as leverage and liquidity. Content on this page is for reference only and does not constitute investment advice. Product availability and access may vary by region and applicable regulations.